Medical Marijuana Inhaler Coming to Israel
By Josefin Dolsten November 29, 2016
— Teva Pharmaceutical Industries of Israel will market and distribute a cannabis inhaler in the country, becoming the first major medical company in the world to do so.
Teva signed an agreement to exclusively market and distribute the inhaler developed and manufactured by the Tel Aviv-based company Syqe Medical, the companies said in a statement Monday.
Syqe said it was the first time that a major global pharmaceutical company would market a medical cannabis product, according to The Times of Israel. The inhaler has been used at the Rambam Hospital in Haifa.
Israel’s Health Ministry was expected to approve the device for use by patients at home by 2017.
“Teva Israel is entering the field of medical cannabis out of a deep commitment to patients coping with pain, which is one of the company’s core therapeutic areas,” said its CEO, Avinoam Sapir, according to The Times of Israel.
The Forward is free to read, but it isn’t free to produce
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward.
At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse.
Readers like you make it all possible. We’ve started our Passover Fundraising Drive, and we need 1,800 readers like you to step up to support the Forward by April 21. Members of the Forward board are even matching the first 1,000 gifts, up to $70,000.
This is a great time to support independent Jewish journalism, because every dollar goes twice as far.
— Rachel Fishman Feddersen, Publisher and CEO
2X match on all Passover gifts!
Dive In
-
Fast Forward Rabbi who left Harvard calls Trump threat ‘reasonable’ — but warns of looming consequences
-
Fast Forward Secretive GOP firm distorts Democratic candidate’s views on Israel in NJ governor race
-
Fast Forward Trump administration to review nearly $9 billion in Harvard funding over campus antisemitism
-
Fast Forward Cornell pro-Palestinian student leader opts to leave US, as Columbia ‘self-deportee’ makes her case to return
Most Popular
- 1
Film & TV What Gal Gadot has said about the Israeli-Palestinian conflict
- 2
News A Jewish Republican and Muslim Democrat are suddenly in a tight race for a special seat in Congress
- 3
Fast Forward The NCAA men’s Final Four has 3 Jewish coaches
- 4
Culture How two Jewish names — Kohen and Mira — are dividing red and blue states
In Case You Missed It
-
Yiddish כ׳בענק נאָך די וועלטלעכע ייִדן וואָס האָבן אָפּגעריכט אַ טראַדיציאָנעלן סדר Longing for those secular Jews who led a traditional seder
מײַן פֿעטער יונה האָט נישט געהיט שבת און כּשרות אָבער בײַם אָפּריכטן דעם סדר האָט ער געקלונגען ווי אַ פֿרומער ייִד
-
Fast Forward Rabbi who left Harvard calls Trump threat ‘reasonable’ — but warns of looming consequences
-
Fast Forward Secretive GOP firm distorts Democratic candidate’s views on Israel in NJ governor race
-
Fast Forward Trump administration to review nearly $9 billion in Harvard funding over campus antisemitism
-
Shop the Forward Store
100% of profits support our journalism
Republish This Story
Please read before republishing
We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines.
You must comply with the following:
- Credit the Forward
- Retain our pixel
- Preserve our canonical link in Google search
- Add a noindex tag in Google search
See our full guidelines for more information, and this guide for detail about canonical URLs.
To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.